Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide for treating rheumatoid arthritis.

M E Suarez-Almazor1, E Belseck, B Shea

  • 1Health Services Research, Veterans Affairs Medical Center, Mailbox Station 152, 2002 Holcombe Blvd, Houston, Texas, USA, 77024. mes@bcm.tmc.edu

The Cochrane Database of Systematic Reviews
|October 18, 2000
PubMed
Summary

Cyclophosphamide shows short-term benefits for rheumatoid arthritis patients, improving joint scores. However, severe toxicity limits its use due to a poor benefit-risk ratio compared to other treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.

Communications medicine·2026
Same author

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors.

Seminars in arthritis and rheumatism·2025
Same author

Early COVID-19 pandemic modeling: Three compartmental model case studies from Texas, USA.

Computing in science & engineering·2022
Same author

A Short Report Examining the Introduction of Routine Use of Patient-Reported Outcome Measures in a Mixed Oncology Population.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

The ASAS-OMERACT core domain set for axial spondyloarthritis.

Seminars in arthritis and rheumatism·2021
Same author

<i>trips4health</i>: Protocol of a single-blinded randomised controlled trial incentivising adults to use public transport for physical activity gain.

Contemporary clinical trials communications·2020

Area of Science:

  • Rheumatology
  • Clinical Pharmacology
  • Immunosuppressive Therapy

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease.
  • Effective disease-modifying antirheumatic drugs (DMARDs) are crucial for managing RA.
  • Cyclophosphamide is an immunosuppressive agent with potential applications in autoimmune conditions.

Purpose of the Study:

  • To evaluate the short-term efficacy and safety of cyclophosphamide in rheumatoid arthritis treatment.
  • To compare cyclophosphamide's effects against placebo in RA patients.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and controlled clinical trials (CCTs).
  • Searched major databases (Cochrane, Medline, Embase) up to August 2000.
  • Pooled analysis of joint counts, erythrocyte sedimentation rate (ESR), and toxicity data.

Related Experiment Videos

Main Results:

  • Cyclophosphamide significantly improved tender and swollen joint scores (SMDs -0.57 and -0.59).
  • A trend towards reduced ESR was observed, but not statistically significant.
  • Higher rates of withdrawal due to adverse reactions were noted with cyclophosphamide, though not statistically significant.

Conclusions:

  • Cyclophosphamide demonstrates clinical and statistical benefits in RA disease activity.
  • Its efficacy is comparable to some DMARDs but less than methotrexate.
  • Severe toxicity, including hemorrhagic cystitis and myelosuppression, results in a poor benefit-risk ratio compared to other antirheumatic agents.